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Edited by Varda RotterAbstract Small ubiquitin-like modiﬁer-1 (SUMO-1) conjuga-
tion to the tumor suppressor protein p53 seems to be regulated by
murine double minute 2 homologue (Mdm2). It is thought that
the physical association of Mdm2 with p53 is important for the
enhancement of SUMO-1 conjugation to p53. However, mutant
p53 that does not associate with Mdm2 is still sumoylated, albeit
at a reduced level, suggesting that sumoylation of p53 is
independent of the presence of Mdm2 and there is a direct
association of ubiquitin-conjugating enzyme 9 (Ubc9), an E2
ligase for sumoylation, with p53. Here, we report evidence of the
direct interaction of Ubc9 with p53. Furthermore, we observed
that the interaction of Ubc9 with p53 was regulated by
phosphorylation of p53. In particular, in cells treated with
adriamycin that is a DNA damaging agent and that enhances
phosphorylation of p53 at Ser-20, SUMO conjugation of p53
was severely impaired possibly by reduced aﬃnity of Ubc9 to
p53.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The tumor suppressor p53 plays a signiﬁcant role in the
cellular response to genome damage. The importance of p53 in
maintaining genome integrity is emphasized by the high fre-
quency of p53 mutations observed in many human tumors [1]
and the high rate of tumor development seen in p53 knockout
mice [2].
Although the level of p53 in cells is low under normal con-
ditions, exposure to stress signals such as DNA damage and
heat shock results in an increase in p53 levels because of its
prolonged half-life [3]. The accumulation of p53 is responsible
for increased transcription of p53 responsive genes, including
proteins involved in cell-cycle regulation (e.g., p21waf1) and
apoptosis (e.g., Bax) [4–8]. Murine double minute 2 homo-* Corresponding author. Fax: +81-75-751-3998.
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regulator of p53 [9,10].
The ubiquitin-proteasome system is responsible for the
degradation and rapid turnover of p53 [11], and this is medi-
ated through the association of p53 with Mdm2 [12–14]. The
interaction of Mdm2 and p53 plays a critical role in sup-
pressing the transcriptional activity of p53 [15–17], as well as
the ubiquitination and degradation of p53 [18].
The role of ubiquitination in protein degradation is well
documented and it has recently become clear that a small
ubiquitin-like protein, variously known as small ubiquitin-like
modiﬁer 1 (SUMO-1)/sentrin/GMP1/UBL1/PIC1, can be co-
valently linked to a variety of cellular proteins [19–22]. p53 has
been found to be covalently modiﬁed by SUMO-1 in vitro and
in vivo at lysine 386 [23,24]. This sumoylation is enhanced by the
association of E3 ligases, PIAS family proteins [25,26]. How-
ever, SUMO-1 and ubiquitin modiﬁcation do not occur on the
same lysine residue in p53 although they do in the case of IkBa
[27]. Also, SUMO-1 conjugation to p53 does not seem to alter its
transcriptional activity. Some reports suggest increased p53
activity upon sumoylation, but this remains controversial.
Enhanced p53 sumoylation occurs through direct interaction
with Mdm2 in cells [28] and a p53 mutant that does not in-
teract with Mdm2 is poorly sumoylated. An Mdm2 mutant
with a constitutively activated cryptic nucleolus localization
signal targets p53 to the nucleolus and promotes p53 sumoy-
lation. These data suggest that enhanced sumoylation of p53
by Mdm2 is mediated by targeting p53 to the nucleolus
through the formation of the Mdm2/p53 complex. Addition-
ally, the phosphorylation state of p53 aﬀects its ability to in-
teract with Mdm2. It is known that DNA-dependent protein
kinase, which targets serine residues 15 and 37, reduces the
aﬃnity between p53 and Mdm2, and as a consequence,
phosphorylated p53 is thought to be a poor substrate for
ubiquitination and sumoylation under these conditions.
To clarify the phosphorylation sites on p53 that aﬀects su-
moylation, we focused on the Ser-20, a target of the checkpoint
kinase 2 (Chk2) activated by DNA damage [29]. In addition,
we analyzed the sumoylation of p53 mutants with serine to
glutamic acid substitutions at residues 46 or 392, a change
thought to mimic the phosphorylated state of p53.2. Materials and methods
2.1. Cell line
HEK-293T cells (adenovirus-transformed human embryo kidney cell
line containing endogenous p53) were maintained in DMEM (Nissui)blished by Elsevier B.V. All rights reserved.
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kanamycin (Meiji) at 37 C in 5% CO2 atmosphere.
2.2. Plasmid construction
A pcDNA3 (Invitrogen) based plasmid expressing FLAG-tagged
human p53 (wild type) was provided byDr. Y. Ariumi. The p53mutants
were produced individually using the site-directed mutagenesis system,
Mutan Super Express Km (Takara), together with the generated
pkF18K-p53 as a template. Mutagenetic oligonucleotides (Invitrogen)
used in LA-PCR were: p53S20A, 50-pGGAAACATTTGCAGACC-
TATG-30; p53S20E, 50-pCAGGAAACATTTGAAGACCTATGG-30;
p53S46E, 50-pGATTTGATGCTG-GAGCCGGACG-30 and p53S3-
92E, 50-pCAGAAGGGCCTGACGAAGACTGACATTCTCCAC-30.
All plasmids were sequenced to conﬁrm successful mutagenesis (ABI
prism). FLAG-tagged p53 mutants were subcloned into pcDNA3.
Plasmids encoding Myc-tagged ubiquitin-conjugating enzyme 9 (Ubc9)
and hemagglutinin epitope tag (HA)-tagged SUMO-1were generated as
described previously [30].
2.3. Immunoprecipitations
HEK-293T cells (1 105 per 6 cm-diameter dish) were transfected
using FuGENE6 (Roche) according to the manufacturer’s instruc-
tions. To detect the sumoylated forms of p53, cells were lysed in 1 ml of
RIPA buﬀer [25 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% NP-40,
0.1% SDS, 0.5% sodium deoxycholate, 1 mM dithiothreitol (DTT), 5
mM ethylenediamine tetra-acetic acid (EDTA), 10 mM N-ethylma-
leimide, 200 mM indole-3-acetic acid, and a complete protease inhib-
itor cocktail tablet (Roche)] for 30 min on ice. Cell debris was removed
by centrifugation for 15 min. Lysates were pre-cleared with protein G
beads for 30 min, followed by incubation with antibodies for 1 h at 4
C. Finally, the antibody complexes were captured with protein G
beads for 1 h. Beads-bound proteins were washed four times with
RIPA buﬀer, and immunoprecipitates were eluted and analyzed by
immunoblot (IB). For co-immunoprecipitations, cells were transfected
with 2 lg pcDNA3-FLAG-p53 expression plasmids with or without 2
lg pcDNA3-Myc-Ubc9 expression plasmid. After 36 h of culture, cells
were lysed in 1 ml of immunoprecipitated (IP) buﬀer [50 mM Tris–HCl
(pH 8.0), 150 mM NaCl, 0.5% Triton X-100, 1 mM DTT, 1 mM
EDTA, and a complete protease inhibitor cocktail tablet]. Lysates were
analyzed by immunoprecipitation followed by IB assay.
2.4. Adriamycin treatment
HEK-293T cells were transfected with the expression plasmid en-
coding FLAG-tagged p53WT. After 24 h of culture, cells were treated
with 0.64 lM of adriamycin for another 24 h, and cell lysates were
prepared for immunoprecipitation and IB assay.Fig. 1. Phosphorylation mimicked form of p53 at Ser-20 suppresses SUMO
expressing FLAG-tagged wild-type p53 (WT), or the p53 mutants S20E, S2
SUMO-1. Thirty six hours after transfection, cell lysates were prepared an
cipitates were subjected to 7.5% SDS–PAGE followed by analysis by IB using
the ﬁlter shown in the top panel, the same ﬁlter was re-probed with the anti2.5. Materials
Rat anti-HA (3F10, Roche), mouse anti-Myc (9E10, Santa Cruz),
mouse and rabbit anti-FLAG (Sigma) antibodies were purchased.
Phospho-Ser20-p53 antibody was generously provided by Dr. Y. Taya.
Horseradish peroxidase (HRP)-linked goat antibodies to rat IgG were
acquired from Jackson ImmunoResearch Lab. HRP-linked goat an-
tibodies to mouse or rabbit IgG were purchased from Amersham
Biosciences. Adriamycin was purchased from Sigma.3. Results and discussion
To examine the sumoylation of FLAG-tagged p53, plasmids
encoding wild-type or mutant p53 and HA-tagged SUMO-1
were transiently co-expressed in cells. Expression of FLAG-
tagged p53 was conﬁrmed by immunoprecipitation followed
by immunoblotting. Two bands, one with the expected size of
wild-type FLAG-p53 and another more slowly migrating
band, were detected (Fig. 1). The apparent molecular weight of
the upper band was higher in cells exogenously expressing
SUMO-1. Because the upper band was detected by anti-HA,
this band was the sumoylated form of p53 (Fig. 1, middle
panel). Cells expressing p53S46E and p53S392E were similar
to wild-type p53, but in the cells producing p53S20E, the upper
band was very weak. This was further conﬁrmed by the ob-
servation that the upper band in cells expressing p53S20E, but
not p53S20A, was detected as a weak signal (Fig. 1, lower
panel). These data suggested that phosphorylation of p53 at
Ser-20 severely impaired SUMO-1 conjugation. Previously, it
was shown that sumoylation of p53 was aﬀected by its inter-
action with Mdm2 in cells [28]. A p53 mutant that poorly binds
Mdm2 undergoes deﬁcient sumoylation. These data suggest
that Mdm2 plays an important role in the enhancement of p53
sumoylation. Since a p53 mutant that does not interact with
Mdm2 is still sumoylated in vitro, Mdm2 does not seem to be
an essential component for the sumoylation of p53 but rather
enhances sumoylation. Since Ubc9, the E2 ligase for the SU-
MO-conjugation reaction, was shown to associate with a tar-
get molecule for sumoylation, the association of Ubc9 with-1 conjugation. HEK-293T cells were transfected with 2 lg of plasmid
0A, S46E, or S392E with (+) or without ()) plasmids expressing HA-
d IP with anti-FLAG mouse monoclonal antibody. The immunopre-
the anti-FLAG rabbit polyclonal antiserum (top panel). After stripping
-HA antibody (middle panel).
Fig. 3. Sumoylation of p53 is repressed by adriamycin treatment.
HEK-293T cells were transfected with 5 lg of plasmid expressing
FLAG-tagged wild-type p53. Twenty-four hours after transfection,
cells were treated with (+) or without ()) 0.64 lM adriamycin for 24 h,
and cell lysates were prepared and IP with anti-FLAG mouse mono-
clonal antibody. The immunoprecipitates as well as the whole cell ly-
sates were subjected to 7.5% SDS–PAGE and then analyzed by IB
using anti-FLAG rabbit polyclonal antiserum.
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in the presence of 35S-methionine. The interaction of Ubc9
with 35S-labeled wild-type p53, p53S20E and p53S20A was
analyzed by GST pull-down analysis (Fig. 2A). Ubc9 bound
all the p53 products tested with slightly varying aﬃnity. The
aﬃnity of Ubc9 towards p53S20E was reduced by half
(Fig. 2B). Because there is no Mdm2 in this assay system, there
appears to be a direct interaction between Ubc9. The inter-
action of Ubc9 and p53 was also observed in vivo (Fig. 2C).
Cells were co-transfected with Myc-tagged Ubc9 together with
FLAG-tagged p53, p53S20A or p53S20E. Cells lysates pre-
pared from these cells were then analyzed by immunoprecipi-
tation followed by IB. Comparing to the amount of wild-type
p53 and p53S20A in the complexes co-precipitated with Ubc9,
that of p53S20E was signiﬁcantly reduced. However, this result
may not support the possible direct interaction of p53 with
Ubc9, since Ubc9 is known to interact with Mdm2.
The Ser-20 of p53 can be directly phosphorylated by Chk2 in
response to DNA damage [29]. To address whether sumoyla-
tion of p53 is suppressed by phosphorylation of p53 at Ser-20,
we analyzed the sumoylation of p53 after adriamycin treat-
ment. In order to determine whether adriamycin treatment led
to phosphorylation of Ser-20 of p53, HEK-293T cells were
transfected with a plasmid expressing FLAG-tagged wild-type
p53 and treated with 0.64 lM of adriamycin at 24 h post-
transfection. Adriamycin treatment was performed for 24 h
and the whole cell lysates were prepared for analysis by IB
assay with phospho-Ser20 p53 antibody (Fig. 3, upper panel).
Ser-20 phosphorylation following adriamycin treatment was
observed. We next analyzed sumoylation of p53 in cells treated
with adriamycin. Sumoylation of p53 was signiﬁcantly de-
creased after adriamycin treatment (Fig. 3, lower panel),Fig. 2. Association of Ubc9 with wild-type and mutant p53 in vitro and in vivo
incubated with GST or GST-Ubc9. (B) The GST pull-down complexes were
times independently and data were shown with error bars. (C) HEK-293T cel
type p53 (WT), S20E, or S20A mutants together with (+) or without ()) Myc-
lysates were prepared and subjected to IP with anti-Myc antibody. The immu
PAGE followed by IB using anti-FLAG rabbit polyclonal antiserum.suggesting that it was repressed by Chk2-mediated phosphor-
ylation of p53 at Ser-20.
It seems that Mdm2 binding to p53 is important for the
enhancement of SUMO conjugation to p53 in cells. Since
Mdm2 associates with Ubc9, it is possible that Mdm2 en-
hances the recruitment of Ubc9 to p53. However, this is less
likely because sumoylation of p53 in vitro in the presence of
Ubc9 was not enhanced by Mdm2. We observed a direct in-
teraction of Ubc9 with p53 in vitro and this interaction was
aﬀected by the phosphorylation state of p53. Considering these
results and previous reports, it is likely that Ubc9 directly as-
sociates and functions to sumoylate p53. Mdm2 may regulate. (A) 35S-labeled wild-type p53 and p53 mutants, S20E and S20A, were
quantitated by imaging analyzer. The experiment was conducted three
ls were transfected with 2 lg of plasmid expressing FLAG-tagged wild-
tagged Ubc9 expression plasmid. Thirty six hours after transfection, cell
noprecipitates and the whole cell lysates were subjected to 7.5% SDS–
18 J.-Y. Lin et al. / FEBS Letters 573 (2004) 15–18this process through at least two mechanisms, enhanced p53
nuclear localization and a mechanism yet to be clariﬁed.
In the present study, we suggest that phosphorylation of p53
at Ser-20 reduces sumoylation. This may result from either the
lack of an interaction of p53 with Mdm2 or reduced aﬃnity of
Ubc9 to p53 in vivo. Although the physiological roles of su-
moylation of p53 are yet to be fully determined, the reduced
sumoylation of p53S20E suggests an intrinsic role of sumoy-
lation upon stress induced conditions including DNA damage.
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